Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SPRO with free AI briefings, catalyst countdowns, and dilution alerts.

SPRO · Spero Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$107.9M Cash on Hand
13.5mo Cash Runway
1.6% Short Interest
$5.33 Analyst Target (3)
Follow SPRO by email Get an email when SPRO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SPRO, unsubscribe in one click. Privacy

📣 What SPRO Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
TBP-PI-HBr Urinary Tract Infection Phase 3 · NCT06059846 Completed
Dummy Infusion Urinary Tract Infection Phase 3 · NCT06059846 Completed
TBPM-PI-HBr Complicated Urinary Tract Infection Phase 3 · NCT03788967 Completed
Imipenem-cilastatin Urinary Tract Infection Phase 3 · NCT06059846 Completed
SPR720 Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Phase 2 · NCT05496374 Completed
Tebipenem Pivoxil Hydrobromide Diabetes Phase 1 · NCT04919954 Completed
Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)… Healthy Volunteers Phase 1 · NCT04421885 Completed
SPR994 Healthy Volunteers Phase 1 · NCT03395249 Completed
SPR741 Healthy Volunteers Phase 1 · NCT03376529 Completed
SPR720 for SAD Healthy Volunteers Phase 1 · NCT03796910 Completed
Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)… Healthy Volunteers Phase 1 · NCT04421885 Completed
Tebipenem tablet form Relative Bioavailability Phase 1 · NCT05296382 Completed
SPR206 Renal Impairment Phase 1 · NCT04865393 Completed
SPR720 for MAD Healthy Volunteers Phase 1 · NCT03796910 Completed
Orapenem® Healthy Volunteers Phase 1 · NCT03395249 Completed
Moxifloxacin TQT Study Phase 1 · NCT04238195 Completed

Also used in these trials (approved or third-party drugs, not SPRO's own candidates): Ertapenem Sodium, Piperacillin Sodium, Tazobactam Sodium, Omeprazole, Ceftazidime, Aztreonam, Azithromycin.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SPRO holds $107.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $24M/quarter from operations, an estimated runway of 13.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 28 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SPRO files for a raise →

👥 Who Owns SPRO

Insiders 8.4% Institutions 38.6% Public and other holders 53%
HolderTypeShares% of sharesAs of
GSK PLC Institution (13G, 5%+) 9,190,606 15.77% 2025-03-27
Pfizer Inc Institution (13F) 2,362,348 4.05% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 2,036,226 3.49% 2026-09-30
Mackenzie Financial Corporation Institution (13F) 1,831,254 3.14% 2026-09-30
Sath Shukla
CEO & President
Insider 1,736,883 2.98% 2025-02-03
Renaissance Technologies, LLC Institution (13F) 1,409,783 2.42% 2026-09-30
Affinity Asset Advisors, Llc Institution (13F) 1,300,000 2.23% 2026-09-30
Arrowstreet Capital, Limited Partnership Institution (13F) 997,123 1.71% 2026-09-30
Esther Rajavelu
Chief Executive Officer and Chief Financ · +498,000 options
Insider 946,000 1.62% 2026-11-06
Verdad Advisers, LP Institution (13F) 805,702 1.38% 2026-09-30
Raymond James Financial, Inc. Institution (13F) 755,633 1.30% 2026-09-30
Timothy Keutzer
Chief Operating Officer
Insider 742,506 1.27% 2026-02-06

Share count 58,264,577 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-10
filed 2026-11-10
HO WILLIAM
Option award (A) 100,000 – –
2026-11-09
filed 2026-11-10
Rajavelu Esther
Sale (S) 40,851 $1.04 946,000
2026-08-03
filed 2026-08-06
Zack Debra
Award (A) 162,311 – 162,311
2026-08-03
filed 2026-08-06
Zack Debra
Option award (A) 324,675 – –
2026-06-23
filed 2026-06-25
Smith Cynthia
Option award (A) 20,000 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-06-18 Utebzi NDA -18.2% +8.1% -4.3%

Browse all historical PDUFA outcomes →

Get the full SPRO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SPRO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.